| Manufacturing Network Grant | Steve Feldman | Laboratory for Cell and Gene Medicine: A partner in the California Cell and Gene Therapy Manufacturing Network |
$2,000,000 |
| Foundation – Discovery Stage Research Projects | Xiaojie Qiu | Mapping and modeling endothelial cell fate decisions for pulmonary arterial hypertension |
$1,540,798 |
| Foundation – Discovery Stage Research Projects | Dr. Marius Wernig MD, PhD | Developing a microglia replacement therapy |
$1,378,365 |
| Discovery Research Projects | Dr. Albert J Wong | Identifying HLA Class I Restricted Peptides That Induce CD8+ T Cells Against SARS-CoV-2 |
$249,999 |
| Discovery Research Projects | Dr. Helen M Blau | Application of PGE2/BPV, a muscle stem cell targeting therapeutic, to the treatment of COVID-19 associated diaphragm atrophy |
$149,996 |
| Alpha Stem Cell Clinics Network Expansion | Dr. Matthew H Porteus | The Stanford Alpha Stem Cell Clinic |
$6,920,810 |
| Quest – Discovery Stage Research Projects | Dr. Robert Negrin MD | Orthogonal IL2 Receptor Transduced Regulatory T Cells for Clinical Application |
$1,920,652 |
| Quest – Discovery Stage Research Projects | Dr. Michael F Clarke | Developing a breast cancer stem cell drug |
$2,053,727 |
| Quest – Discovery Stage Research Projects | Dr. Judith A Shizuru | Targeted Immunotherapy-Based Blood Stem Cell Transplantation |
$1,341,910 |
| Quest – Discovery Stage Research Projects | Ansuman Satpathy | Preclinical development of an exhaustion-resistant CAR-T stem cell for cancer immunotherapy |
$1,420,200 |
| Quest – Discovery Stage Research Projects | Dr. Bertha Chen | iPSC-derived smooth muscle cell progenitor conditioned medium for treatment of pelvic organ prolapse |
$1,420,200 |
| Quest – Discovery Stage Research Projects | Dr. Sarah C Heilshorn | Injectable, autologous iPSC-based therapy for spinal cord injury |
$789,000 |
| Quest – Discovery Stage Research Projects | Dr. Stanley Qi | A novel hybrid CRISPR tool for gene network perturbation and hiPSC engineering |
$704,661 |
| Quest – Discovery Stage Research Projects | Dr. Marius Wernig MD, PhD | A universally applicable skin sheet for Dystrophic Epidermolysis Bullosa via next-generation gene editing, iPS cell technology and tissue engineering |
$1,229,040 |
| Quest – Discovery Stage Research Projects | Dr. Phillip C Yang | Hypoxia-specific Production of Exosomes from iPSC-derivatives for Myocardial Repair |
$1,418,023 |
| Quest – Discovery Stage Research Projects | Kathleen M Sakamoto | Small Molecules to inhibit Nemo-like Kinase for Treatment of Diamond Blackfan Anemia |
$846,638 |
| Quest – Discovery Stage Research Projects | Alan G Cheng | Modulation of the Wnt pathway to restore inner ear function |
$1,389,416 |
| Quest – Discovery Stage Research Projects | Dr. Katja Weinacht | Regenerative Thymic Tissues as Curative Cell Therapy for Patients with 22q11 Deletion Syndrome |
$1,251,720 |
| Quest – Discovery Stage Research Projects | Dr. Philip Arden Beachy PhD | Pluripotent stem cell-derived bladder epithelial progenitors for definitive cell replacement therapy of bladder cancer |
$1,265,436 |
| Quest – Discovery Stage Research Projects | Dr. Kyle M Loh | Towards hepatocyte cell replacement therapy: developing a renewable source of human hepatocytes from pluripotent stem cells |
$1,968,456 |
| Quest – Discovery Stage Research Projects | Dr. Helen M Blau | Stimulating endogenous muscle stem cells to counter muscle atrophy |
$2,198,687 |
| Quest – Discovery Stage Research Projects | Dr. Mark Mercola | Multipotent Cardiovascular Progenitor Regeneration of the Myocardium after MI |
$1,809,234 |
| Quest – Discovery Stage Research Projects | Dr. Matthew H Porteus | Genome Editing to Correct Cystic Fibrosis Mutations in Airway Stem Cells |
$1,968,456 |
| Quest – Discovery Stage Research Projects | Dr. Roel Nusse | Preclinical development of human hepatocyte progenitor cells for cell therapy |
$1,651,211 |
| Quest – Discovery Stage Research Projects | Dr. Rosa Bacchetta | GENE EDITING FOR FOXP3 IN HUMAN HSC |
$984,228 |
| Quest – Discovery Stage Research Projects | Professor Hiromitsu Nakauchi | Novel Rejuvenated T Cell Immunotherapy for Lung Cancer |
$1,968,456 |
| Inception – Discovery Stage Research Projects | Professor Hiromitsu Nakauchi | Optimizing self-renewal signaling kinetics to stabilize ex vivo hematopoietic stem cell expansion |
$210,906 |
| Inception – Discovery Stage Research Projects | Guillem Pratx | Novel metabolic labeling method for tracking stem cells to irradiated salivary glands using PET |
$229,227 |
| Inception – Discovery Stage Research Projects | Dr. Helen M Blau | Prodrug innovation to target muscle stem cells and enhance muscle regeneration |
$235,834 |
| Inception – Discovery Stage Research Projects | Jeffrey L Goldberg | Embryonic Stem Cells for Corneal Endothelial Degeneration |
$235,836 |
| Inception – Discovery Stage Research Projects | Dr. Philip Arden Beachy PhD | Curing bladder cancer by replacing corrupted urothelium with differentiated hES cells |
$210,906 |
| Inception – Discovery Stage Research Projects | Dr. Bertha Chen | Autologous iPSC-based therapy for radiation induced bladder injury |
$235,836 |
| Inception – Discovery Stage Research Projects | Dr. Phillip C Yang | Activation of patient-specific endogenous myocardial repair through the exosomes generated from the hypoxic iPSC-derived cardiomyocytes (iCMs). |
$234,619 |
| Tool Translational Research Projects | Professor Irving L Weissman MD | Purification of Human Hematopoietic Stem Cells (HSCs) for Clinical Stem Cell Transplantation |
$1,347,722 |
| Tool Translational Research Projects | Dr. Joseph C. Wu | A Novel, Robust and Comprehensive Predictive Tool Using Human Disease-Specific Induced Pluripotent Stem Cells for Preclinical Drug Screening |
$975,000 |
| Therapeutic Translational Research Projects | Sergiu P Pasca | A targeted antisense oligonucleotide therapeutic strategy for Timothy syndrome |
$5,596,629 |
| Therapeutic Translational Research Projects | Natalia Gomez-Ospina | Toward a Cure for Gaucher Disease Type 1: Autologous Transplantation of Genome Edited Hematopoietic Stem Cells |
$4,696,296 |
| Therapeutic Translational Research Projects | Walter Park | Enhanced Autologous Pancreatic Islet Transplantation and Survival for Diabetes Mellitus Therapy |
$6,054,165 |
| Therapeutic Translational Research Projects | Dr. Theodore Leng | NeuBright, a purified allogeneic cell therapy product for treatment of Dry Age-related Macular Degeneration |
$4,235,758 |
| Therapeutic Translational Research Projects | Dr. Bertha Chen | Autologous iPSC-derived smooth muscle cell therapy for treatment of urinary incontinence |
$5,977,155 |
| Therapeutic Translational Research Projects | Dr. Anthony E. Oro | DEBCT: Genetically Corrected, Induced Pluripotent Cell-Derived Epithelial Sheets for Definitive Treatment of Dystrophic Epidermolysis Bullosa |
$5,107,353 |
| Therapeutic Translational Research Projects | Dr. Albert J Wong | 2nd Generation Vaccine for the Treatment of Glioblastoma |
$2,929,889 |
| SPARK | Paul J. Utz | Stem Cell and Regenerative Medicine- High School Summer Research Internship |
$490,458 |
| SPARK | Paul J. Utz | Stem Cell and Regenerative Medicine- Summer Research Internship |
$350,482 |
| Conference II | Dr. Everett H. Meyer | Cellular Immune Tolerance Symposium |
$50,000 |
| Conference II | Dr. Joseph C. Wu | Stanford Drug Discovery Symposium 2024 |
$15,000 |
| Conference II | Dr Ngan F Huang | Bay Area Stanford Regenerative Medicine Conference for Students—A TERMIS-AM Ambassador’s Conference |
$3,320 |
| Conference II | Dr. Everett H. Meyer | Cellular Immune Tolerance Symposium |
$31,225 |
| Conference II | Dr. Joseph C. Wu | Stanford Drug Discovery Symposium 2023 |
$50,000 |
| Conference II | Dr. Joseph C. Wu | Stanford Drug Discovery Symposium 2022 |
$29,408 |
| Conference II | Dr. Joseph C. Wu | 2018 Stanford Drug Discovery and Stem Cell Technology Conference |
$15,000 |
| Conference II | Dr. Samuel Strober | Third International Workshop on Clinical Tolerance |
$29,500 |
| Conference II | Dr. Joseph C. Wu | 2017 Stanford Drug Discovery and Stem Cell Technology Conference |
$2,359 |
| Conference II | Dr. Joseph C. Wu | Drug Discovery & Stem Cell Models for Cardiovascular Disease Conference |
$7,500 |
| Clinical Trial Stage Projects | Dr. Reena Parada Thomas | Phase I Trial of Locoregionally Delivered Autologous B7-H3 CAR T Cells (B7-H3CART) in Adults with Recurrent Glioblastoma Multiforme |
$11,999,991 |
| Clinical Trial Stage Projects | Anusha Kalbasi | Stem-Derived IL13Ra2 Chimeric Antigen Receptor T cells for Patients with Melanoma and Advanced Solid Tumors |
$10,211,085 |
| Clinical Trial Stage Projects | Dr. Matthew H Porteus | Reduced intensity conditioning with JSP191 prior to TCRαβ+ T-cell/CD19+ B-cell depleted hematopoietic stem cell transplant for Fanconi Anemia patients |
$10,642,420 |
| Clinical Trial Stage Projects | Alice Bertaina | Sequential same donor αβdepleted-HSCT from an HLA-partially matched donor allowing immunosuppression free kidney transplant |
$11,998,188 |
| Clinical Trial Stage Projects | Dr. Rosa Bacchetta | Phase 1 Study of Autologous CD4LVFOXP3 in Participants with IPEX Syndrome |
$11,999,179 |
| Clinical Trial Stage Projects | Dr. Joseph C. Wu | A Phase I, Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes in PaTients with ChrOnic Ischemic Left VentRicular Dysfunction (HECTOR) |
$6,987,507 |
| Clinical Trial Stage Projects | Crystal Mackall | Phase 1 Clinical Trial of Autologous GD2 Chimeric Antigen Receptor T Cells for Diffuse Intrinsic Pontine Gliomas and Spinal Diffuse Midline Glioma |
$11,998,310 |
| Clinical Trial Stage Projects | Dr. Matthew H Porteus | Phase 1/1b study of T-allo10 infusion after HLA-partially matched abdepleted-HSCT in children and young adults with hematologic malignancies. |
$10,563,822 |
| Clinical Trial Stage Projects | Dr. Gary Steinberg | Safety and Tolerability Study of Neural Stem Cells (NR1) in Subjects with Chronic Ischemic Subcortical Stroke |
$11,998,988 |
| Clinical Trial Stage Projects | Dr. Judith A Shizuru | A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$1,113,487 |
| Clinical Trial Stage Projects | Dr. Everett H. Meyer | Induction of Tolerance by Combinatorial Therapy w/ Donor Stem Cells and Expanded Recipient Treg cells in HLA-mismatched Kidney Transplant Recipients |
$8,920,000 |
| Clinical Trial Stage Projects | Dr. David B. Miklos | Phase 1 Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults with Recurrent or Refractory B Cell Malignancies |
$11,034,982 |
| Clinical Trial Stage Projects | Dr Robert Lowsky | Induction of Tolerance to Combined Kidney and Hematopoietic Progenitor Cell Transplants from HLA Haplotype Matched Living Donors |
$6,653,266 |
| Late Stage Preclinical Projects | Dr. Matthew H Porteus | Autologous Gene Corrected Sinus Basal Cells to Treat Serious Cystic Fibrosis Sinus Disease |
$6,000,000 |
| Late Stage Preclinical Projects | Natalia Gomez-Ospina | Genome Editing of Autologous Hematopoietic Stem Cells to Treat Severe Mucopolysaccharidosis type 1 (Hurler Syndrome) |
$5,444,353 |
| Late Stage Preclinical Projects | Dr. Rosa Bacchetta | IND-enabling activities for a Phase 1 Study of Autologous CD4LVFOXP3 T Cells in Subjects with IPEX Syndrome |
$5,002,496 |
| Late Stage Preclinical Projects | Dr. Matthew H Porteus | Genome Editing of Autologous Hematopoietic Stem Cells to Treat Sickle Cell Disease |
$4,849,363 |
| Late Stage Preclinical Projects | Dr. Gary Steinberg | Intraparenchymal NR1 Stem Cell Therapy for Chronic Subcortical Ischemic Stroke |
$5,300,000 |
| Preclinical Development Awards | Dr. Matthew H Porteus | Pre-clinical development of gene correction therapy of hematopoietic stem cells for SCID-X1 |
$874,877 |
| Tools and Technologies III | Sarah Heilshorn | Injectable Hydrogels for the Delivery, Maturation, and Engraftment of Clinically Relevant Numbers of Human Induced Pluripotent Stem Cell-Derived Neural Progenitors to the Central Nervous System |
$1,347,767 |
| Tools and Technologies III | Dr. James C. Dunn Dr. | Skin-derived precursor cells for the treatment of enteric neuromuscular dysfunction |
$772,098 |
| Tools and Technologies III | Dr. Fan Yang PhD | Injectable Macroporous Matrices to Enhance Stem Cell Engraftment and Survival |
$1,434,235 |
| Tools and Technologies III | Dr. Joseph C. Wu | Macaca mulatta as advanced model for predictive preclinical testing of engineered cardiac autografts and allografts |
$1,689,744 |
| Tools and Technologies III | Dr. Anthony E. Oro | A Chromatin Context Tool for Predicting iPS Lineage Predisposition and Tissue Graftability |
$1,391,125 |
| Tools and Technologies III | Professor Irving L Weissman MD | Identification and isolation of transplantable human hematopoietic stem cells from pluripotent cell lines; two steps from primitive hematopoiesis to transplantable definitive cells, and non-toxic conditioning of hosts for hematopoeitic stem cell transp… |
$1,271,952 |
| Conference | Dr. Joseph C. Wu | Cardiovascular Tissue Engineering Symposium |
$25,000 |
| Conference | Hank Greely | Stem Cell Policy: Understanding the Scientific and Legal Challenges Ahead |
$5,838 |
| Conference | Dr. Thomas A. Rando MD, PhD | Keystone Symposia, ‘The Life of a Stem Cell: From Birth to Death’ |
$50,000 |
| Conference | Dr. Joseph C. Wu | Cardiovascular Regenerative Medicine Symposium |
$9,000 |
| Conference | Dr. Fan Yang PhD | 2014 Materials Research Society (MRS) Spring Meeting:
Symposium Y: Biomaterials for Biomolecule Delivery and Understanding Cell-Niche Interactions |
$10,000 |
| Conference | Dr. Thomas A. Rando | Third Annual Symposium on Regenerative Rehabilitation |
$20,000 |
| Conference | Dr. Julien Sage | 3rd International RB conference |
$10,000 |
| Genomics Centers of Excellence Awards (R) | Dr. Michael P Snyder PhD | Center of Excellence for Stem Cell Genomics – Stanford |
$22,787,914 |
| Disease Team Planning | Dr. Robert Robbins | {REDACTED} Cardiovascular Regenerative Team |
$25,119 |
| Disease Team Planning | Dr. Thomas A. Rando MD, PhD | Stem Cell Therapy for Muscular Dystrophy |
$0 |
| Major Facilities | Dr. John L. Hennessy | Stanford SIM1 Building |
$43,578,000 |
| Basic Biology V | Dr. Helen M Blau | Mass Cytometry to Delineate the Human Muscle Stem Cell Hierarchy and Dysfunction in Aging |
$1,175,357 |
| Basic Biology V | Dr. Marius Wernig MD, PhD | Mechanisms of human induced neuronal cell reprogramming |
$1,178,370 |
| Basic Biology V | Dr. Gary Steinberg | Paracrine and synaptic mechanisms underlying neural stem cell-mediated stroke recovery |
$1,178,370 |
| Basic Biology V | Xinnan Wang | Misregulated Mitophagy in Parkinsonian Neurodegeneration |
$1,174,943 |
| Disease Team Therapy Development III | Professor Irving L Weissman MD | Clinical Investigation of a Humanized Anti-CD47 Antibody in Targeting Cancer Stem Cells in Hematologic Malignancies and Solid Tumors |
$6,505,568 |
| Patent Assistance Fund Awards | Katharine Ku | Funding for Patent Applications for CIRM-funded Inventions out of Stanford University |
$3,525 |
| Early Translational IV | Dr. Michele Calos | Engineered iPSC for therapy of limb girdle muscular dystrophy type 2B |
$1,876,253 |
| Tissue Collection for Disease Modeling | Dr. Joseph C. Wu | Tissue Collection for Accelerating iPSC Research in Cardiovascular Diseases |
$1,291,832 |
| Tissue Collection for Disease Modeling | Dr. Joachim Franz Hallmayer | Induced pluripotent stem cells from children with autism spectrum disorders |
$530,265 |
| New Faculty Physician Scientist | Alan G Cheng | Enhancing hair cell regeneration in mouse and human inner ear |
$3,088,525 |
| New Faculty Physician Scientist | Michelle Monje | White matter neuroregeneration after chemotherapy: stem cell therapy for “chemobrain” |
$2,800,526 |
| Creativity Awards | Paul J. Utz | SIMR Program: Stem Cell & Developmental Biology Research Internships |
$340,611 |
| Basic Biology IV | Dr. Gerald R. Crabtree | Mechanism and Utility of Direct Neuronal Conversion with a MicroRNA-Chromatin Switch |
$1,392,150 |
| Basic Biology IV | Dr. Roel Nusse | Asymmetric stem cell division oriented by a local self-renewing signal |
$1,038,600 |
| Basic Biology IV | Dr. Howard Y. Chang | Long noncoding RNAs for pluripotency and cell fate commitment |
$1,386,627 |
| Basic Biology IV | Ben A Barres | Phenotyping Human Astrocytes in Health and Disease |
$0 |
| Basic Biology IV | Alexander Robert Dunn | Role of mechanical signaling in stem cell self-renewal and differentiation |
$1,062,998 |
| Basic Biology IV | Dr. Anne Brunet | Energy metabolism and aging pathways in human stem cell reprogramming and differentiation |
$1,414,044 |
| Basic Biology IV | Michael Cleary | Prostaglandin pathway regulation of self-renwal in hematopoietic and leukemia stem cells |
$1,244,455 |
| Basic Biology IV | Michelle Monje | Stem Cell Mechanisms Governing Discrete Waves of Gliogenesis in the Childhood Brain |
$1,264,248 |
| Disease Team Therapy Development – Research | Dr. Joseph C. Wu | Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$19,060,330 |
| Disease Team Therapy Development – Research | Dr. Judith A Shizuru | A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$18,990,683 |
| Early Translational III | Dr. Joseph C. Wu | Heart Repair with Human Tissue Engineered Myocardium |
$4,395,080 |
| Early Translational III | Professor Helen M. Blau PhD | Local Delivery of Rejuvenated Old Muscle Stem Cells to Increase Strength in Aged Patients |
$1,825,283 |
| Early Translational III | Dr. Bertha Chen | Autologous iPSC Therapy for Urinary Incontinence |
$4,715,738 |
| Training Grant I-1 | Michael T. Longaker M.D. | Stanford CIRM Training Program |
$3,035,282 |
| Disease Team Therapy Planning I | Dr. Albert J Wong | Recombinant Bispecific Antibody Targeting Cancer Stem Cells for the Therapy of Glioblastoma |
$109,750 |
| Disease Team Therapy Planning I | Dr. Judith A Shizuru | A monoclonal antibody that depletes blood stem cells and enables chemotherapy free transplants |
$90,147 |
| Disease Team Therapy Planning I | Dr. Robert Robbins | Human Embryonic Stem Cell-Derived Cardiomyocytes for Patients with End Stage Heart Failure |
$73,030 |
| Research Training II | Dr. Theo D. Palmer PhD | Stanford CIRM Training Program |
$7,017,629 |
| Basic Biology III | Dr. Aaron J Hsueh | Correlated time-lapse imaging and single cell molecular analysis of human embryo development |
$1,259,733 |
| Basic Biology III | Sean M. Wu | Elucidating Molecular Basis of Hypertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells |
$1,260,537 |
| Basic Biology III | Dr. Michael F Clarke | USP16 controls stem cell number: implications for Down Syndrome |
$1,263,826 |
| Basic Biology III | Dr. Joanna Wysocka PhD | Enhancer-mediated gene regulation during early human embryonic development |
$1,420,618 |
| Tools and Technologies II | Dr. Marius Wernig MD, PhD | Cellular tools to study brain diseases affecting synaptic transmission |
$1,664,382 |
| Tools and Technologies II | Professor Irving L Weissman MD | Antibody tools to deplete or isolate teratogenic, cardiac, and blood stem cells from hESCs |
$1,463,814 |
| Tools and Technologies II | Dr. Brian K. Rutt | Development of Single Cell MRI Technology using Genetically-Encoded Iron-Based Reporters |
$1,833,348 |
| Tools and Technologies II | Dr. Sarah C Heilshorn | Preparation and Delivery of Clinically Relevant Numbers of Stem Cells Using 3D Hydrogels |
$600,695 |
| Tools and Technologies II | Dr. Theo D. Palmer PhD | Development of small molecule screens for autism using patient-derived iPS cells |
$1,797,606 |
| Tools and Technologies II | Dr. Michele Calos | Site-specific integration of Lmx1a, FoxA2, & Otx2 to optimize dopaminergic differentiation |
$1,592,897 |
| Early Translational II | Dr. Michele Calos | Stem Cell Therapy for Duchenne Muscular Dystrophy |
$2,267,261 |
| Research Leadership | Professor Hiromitsu Nakauchi | Generation of functional cells and organs from iPSCs |
$5,426,135 |
| New Faculty I | Dr. Anne Brunet | Molecular mechanisms involved in adult neural stem cell maintenance |
$2,348,435 |
| New Faculty I | Dr. Joanna Wysocka PhD | Trithorax and Polycomb methyltransferase complexes in cell fate determination. |
$2,373,903 |
| New Faculty I | Karl Deisseroth | Bioengineering technology for fast optical control of differentiation and function in stem cells and stem cell progeny |
$2,424,209 |
| New Faculty I | Dr. Howard Y. Chang | Noncoding RNAs in Cell Fate Determination |
$2,985,894 |
| Early Translational I | Dr. Jill Helms | Enhancing healing via Wnt-protein mediated activation of endogenous stem cells |
$6,464,126 |
| Transplantation Immunology | Dr. Kenneth Weinberg | Engineered immune tolerance by Stem Cell-derived thymic regeneration |
$1,271,729 |
| Transplantation Immunology | Dr. Robert Negrin MD | Regulatory T cell induced tolerance to ESC transplantation |
$1,382,658 |
| Transplantation Immunology | Professor Christopher H. Contag | Engineering Embryonic Stem Cell Allografts for Operational Tolerance |
$1,411,338 |
| Transplantation Immunology | Dr. Judith A Shizuru | Purified allogeneic hematopoietic stem cells as a platform for tolerance induction |
$1,233,275 |
| Tools and Technologies I | Professor Helen M. Blau PhD | Regulation of Stem Cell Fate in Bioengineered Arrays of Hydrogel Microwells |
$949,608 |
| Shared Labs | Dr. Renee Reijo Pera PhD | The Stanford University Center for Human Embryonic Stem Cell Research and Education |
$2,439,590 |
| Shared Labs | Prof Vittorio Sebastiano | The Stanford University Center for Human Embryonic Stem Cell Research and Education |
$3,434,600 |
| New Faculty II | Dr. Ching-Pin Chang | VEGF signaling in adventitial stem cells in vascular physiology and disease |
$3,005,695 |
| New Cell Lines | Dr. Renee Reijo Pera PhD | Derivation and comparative analysis of human pluripotent ESCs, iPSCs and SSCs: Convergence to an embryonic phenotype |
$1,409,243 |
| New Cell Lines | Michael T. Longaker M.D. | Derivation and analysis of pluripotent stem cell lines with inherited TGF-b mediated disorders from donated IVF embryos and reprogrammed adult skin fibroblasts |
$1,406,636 |
| New Cell Lines | Dr. Julie Baker | Derivation of hESC Lines with Disease Lesions |
$1,404,725 |
| New Cell Lines | Dr. Michele Calos | Safe, efficient creation of human induced pluripotent stem cells without the use of retroviruses |
$1,406,875 |
| Comprehensive Grant | Professor Irving L Weissman MD | Prospective isolation of hESC-derived hematopoietic and cardiomyocyte stem cells |
$2,471,386 |
| Comprehensive Grant | Dr. Stefan Heller | Generation of inner ear sensory cells from human ES cells toward a cure for deafness |
$2,330,371 |
| Comprehensive Grant | Dr. Roel Nusse | Guiding the developmental program of human embryonic stem cells by isolated Wnt factors |
$1,710,462 |
| Comprehensive Grant | Dr. Renee Reijo Pera PhD | Human oocyte development for genetic, pharmacological and reprogramming applications |
$2,298,411 |
| Comprehensive Grant | Dr. Christopher K. Zarins | Engineering a Cardiovascular Tissue Graft from Human Embryonic Stem Cells |
$2,454,490 |
| Comprehensive Grant | Dr. Theo D. Palmer PhD | Immunology of neural stem cell fate and function |
$2,396,000 |
| Comprehensive Grant | Dr. Julie Baker | Functional Genomic Analysis of Chemically Defined Human Embryonic Stem Cells |
$2,518,303 |
| SEED Grant | Dr. Aaron J Hsueh | Patient-specific cells with nuclear transfer |
$629,653 |
| SEED Grant | Dr. Joseph C. Wu | In Vivo Imaging of Human Embryonic Stem Cell Derivatives and Tumorigenicity |
$623,634 |
| SEED Grant | Dr. Kenneth Weinberg | Embryonic stem cell-derived thymic epithelial cells |
$628,793 |
| SEED Grant | Dr. Mark Kay Dr. | Novel vectors for gene transfer into human ES cells |
$574,737 |
| SEED Grant | Dr. Susan K McConnell | Optimization of guidance response in human embryonic stem cell derived midbrain dopaminergic neurons in development and disease |
$607,363 |
| SEED Grant | Dr. Phillip C Yang | In Vivo Molecular Magnetic Resonance Imaging of Human Embryonic Stem Cells in Murine Model of Myocardial Infarction |
$629,952 |
| SEED Grant | Dr. Joanna Wysocka PhD | Role of Chromatin Modifiers in Regulating Human Embryonic Stem Cell Pluripotency |
$629,952 |
| SEED Grant | Dr. Thomas Wandless | Reprogramming Differentiated Human Cells to a Pluripotent State |
$380,005 |
| SEED Grant | Dr. John P. Cooke | EC regeneration in cerebrovascular ischemia: role of NO |
$476,995 |
| SEED Grant | Dr. Julien Sage | Functions of RB family proteins in human embryonic stem cells |
$498,609 |
| SEED Grant | Dr. Calvin Jay Kuo | Differentiation of Human Embryonic Stem Cells to Intestinal Fates |
$554,176 |
| SEED Grant | Dr. Krishna Shenoy | Technology for hESC-Derived Cardiomyocyte Differentiation and Optimization of Graft-Host Integration in Adult Myocardium |
$572,891 |
| Basic Biology II | Professor Garry P Nolan | Kinase signaling analysis of iPS cell reprogramming and differentiation |
$1,343,100 |
| Basic Biology II | Dr. Aaron J Hsueh | Maturation of Human Oocytes for SCNT and Embryonic Stem Cell Derivation |
$1,309,018 |
| Basic Biology II | Dr. Steven Edward Artandi | Self-renewal and senescence in iPS cells derived from patients with a stem cell disease |
$931,285 |
| Disease Team Research I | Dr. Gary Steinberg | Embryonic-Derived Neural Stem Cells for Treatment of Motor Sequelae following Sub-cortical Stroke |
$17,244,851 |
| Disease Team Research I | Dr. Alfred T Lane | iPS Cell-Based Treatment of Dominant Dystrophic Epidermolysis Bullosa |
$11,039,208 |
| Disease Team Research I | Professor Irving L Weissman MD | Development of Therapeutic Antibodies Targeting Human Acute Myeloid Leukemia Stem Cells |
$18,759,276 |
| Basic Biology I | Dr. Julien Sage | The retinoblastoma (RB) gene family in cellular reprogramming |
$1,357,085 |
| Basic Biology I | Dr. Susan K McConnell | Identification and characterization of human ES-derived DA neuronal subtypes |
$1,404,853 |
| Basic Biology I | Dr. Helen M Blau | Molecular Mechanisms of Reprogramming towards Pluripotency |
$1,408,332 |
| Research Training Grant | Dr. Tushar Desai | CIRM Scholar Training Program |
$5,347,815 |
| Progression Award – Discovery Stage Research Projects | Dr. Helen M Blau | Stimulating endogenous muscle stem cells to counter muscle wasting |
$237,060 |
| Progression Award – Discovery Stage Research Projects | Professor Hiromitsu Nakauchi | Using metabolic pausing for maintaining stable and high-quality pluripotent stem cells |
$208,422 |
